Aroa Biosurgery Ltd. has announced the publication of interim results from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), in the Journal of Trauma and Injury. The study evaluates the safety and effectiveness of Myriad Matrix and Myriad Morcells in complex trauma and acute care surgery. To date, over 450 patients have been enrolled, with the latest publication reporting on 49 patients treated at four level one trauma centers in the United States. The study found that wounds treated with Myriad achieved full vascularized tissue coverage in a median of 22.5 days, typically with a single product application and no device-related complications. Additionally, a cost and performance comparison indicated that Myriad is less expensive per centimeter and delivers clinical outcomes at least equivalent to or better than alternative bioscaffolds. These results have already been presented in the published article.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN68854) on January 22, 2026, and is solely responsible for the information contained therein.